Aldeyra Therapeutics. has filed a patent for compounds and methods to treat inflammatory diseases or disorders. The patent claim has been canceled. GlobalData’s report on Aldeyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aldeyra Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aldeyra Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Aldeyra Therapeutics's grant share as of September 2023 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Treating inflammatory diseases or disorders

Source: United States Patent and Trademark Office (USPTO). Credit: Aldeyra Therapeutics Inc

A recently filed patent (Publication Number: US20230293527A1) describes a method for treating a disease, disorder, or condition by administering a specific compound. The patent claims cover various aspects of this method.

The patent claims state that the method involves administering an effective amount of a compound to a subject in need of treatment. The compound is not specified in the claims, but it is implied that it has therapeutic properties for treating diseases, disorders, or conditions.

Claims 15 and 16 specify that the method is particularly useful for treating psoriasis and psoriatic arthritis, respectively. Psoriasis is a chronic skin condition characterized by red, itchy, and scaly patches, while psoriatic arthritis is a form of arthritis that affects some individuals with psoriasis.

Claim 17 states that the compound or a pharmaceutically acceptable salt thereof is administered as a free base. This suggests that the compound may be in a basic form, which can be important for its stability and effectiveness.

Claim 18 specifies that the compound or its pharmaceutically acceptable salt is administered systemically to the subject. Systemic administration means that the compound is introduced into the body in a way that allows it to circulate throughout the body, potentially reaching the affected areas.

Lastly, claim 19 mentions that the compound or its pharmaceutically acceptable salt is administered orally to the subject. Oral administration is a common route for drug delivery and offers convenience and ease of use for patients.

Overall, the patent claims describe a method for treating diseases, disorders, or conditions by administering a specific compound. The method is particularly useful for treating psoriasis and psoriatic arthritis, and the compound can be administered as a free base, systemically, and orally. It is important to note that the patent claims do not provide specific details about the compound itself, its mechanism of action, or any potential side effects.

To know more about GlobalData’s detailed insights on Aldeyra Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies